Waleria HealthTech
13, Awfis, Ohri Techpark
Madhapur, Hyderabad. India
Website: www.aspurusshatavari.com

Waleria HealthTech is a women-first ingredient company delivering personalized solutions across women’s hormonal transitions, translating women-centric ayurvedic wisdom into clinically validated ingredient solutions. Waleria addresses long-underserved priorities in women’s health, entrepreneurship and economic independence by ensuring women remain represented and empowered across the entire value chain—from ethical sourcing and scientific research to study design and clinical representation. Its consumer-first innovative study design incorporates inputs directly from the end user, ensuring outcomes that are clinically meaningful, commercially relevant and built for modern women’s health markets.

Komal Baldwa is the founder and CEO of Waleria HealthTech. She is a purpose-driven leader working to uplift her tribe and shape the future of women’s health through Waleria. With more than nine years dedicated to advancing women’s sexual and hormonal health, Baldwa is recognized as one of Asia’s pioneering voices in this space. Beyond research, she is transforming the herbal supply chain and innovating clinical study design by placing women at the center—enabling micro women entrepreneurship and their long-term financial independence. Her approach ensures impact begins at the farm level and continues through every stage of the innovation journey. Here, she discusses the aspurus ingredient and other aspects of a women-led company.

NIE: Talk about aspurus and its benefits.

Baldwa: aspurus is a full-spectrum shatavari (Asparagus racemosus) root extract that preserves the plant’s naturally occurring phytoactive profile. Produced using a patent-pending soft extraction process, which enhances key bioactives—standardized to 5 percent shatavarins—while maintaining the structural integrity.

Across three gold standard clinical studies, aspurus has shown to support in hot flashes, brain fog, fatigue, mood changes, energy levels and sexual wellness parameters such as libido and vaginal dryness.

NIE: Please discuss some of the company’s recent studies.

Baldwa: aspurus has been evaluated through multiple (three) human clinical studies designed around real-world women’s experiences across distinct hormonal life stages. In a recent three-month randomized, double-blind, placebo-controlled trial involving more than 150 perimenopausal women, Waleria implemented a uniquely women-centered study design that tracked both symptom intensity and symptom frequency, capturing how symptoms fluctuate and cascade in real life during this transition. aspurus demonstrated a significant reduction in menopausal symptoms, with early improvements observed as early as Day 14. The study captured outcomes across 12 symptom domains and reported meaningful improvements in hot flashes, sleep, mood, fatigue and cognitive discomfort such as brain fog—reflecting the cascading symptom patterns women commonly experience during perimenopause. Benefits were also observed in sexual well-being parameters, including sexual function and vaginal lubrication.

In a separate study, Waleria has also completed one of the first modern placebo-controlled botanical studies focused exclusively on low libido in reproductive-age women, evaluating aspurus at a lower dose. Within four weeks, the study reported improvements across key dimensions of sexual wellness, including arousal, lubrication, orgasm, pleasure and overall satisfaction, alongside increased frequency and quality of sexual encounters. Importantly, this research explored the energy–libido connection, a critical concern for younger women where reduced desire is often linked to fatigue, stress and mood changes.

Together, these studies reflect Waleria’s commitment to building a clinically grounded evidence base for women-focused botanical ingredients across menopause, perimenopause and the reproductive years.

NIE: Aspurus has been honored with a number of awards. What do these recognitions mean to Waleria HealthTech?

Baldwa: aspurus receiving multiple awards (SupplySide Ingredient Idol, NIE New Ingredient Award, Natural Choice Award finalist, Estee Lauder Beauty n You finalist) is more than recognition—it’s a strong validation of what Waleria HealthTech stands for: a scientific breakthrough and a purposeful innovation in women’s health. It reinforces our responsibility to continue contributing credible science to categories that have been neglected for supporting women’s life cycle.

NIE: Waleria HealthTech is a woman-owned company. How does that impact the way the company does business?

Baldwa: Being woman-owned drives Waleria’s commitment to purpose-led innovation, stronger science, and deeper impact—built by women, solutions for women. The company approaches women’s health from lived experience, recognizing that hormonal transitions involve interconnected physiological and emotional processes rather than isolated symptoms.

Consumer-led evidence generation—our study designs are built around women’s lived realities, capturing endpoints that matter most to end users—so the outcomes are both clinically meaningful and commercially relevant.

In short, it directly shapes how we build, validate and deliver women’s health ingredients.

NIE: Is there anything else you would like to add?

Baldwa: Waleria’s research roadmap extends beyond today’s focus areas, with more ongoing clinical studies planned for additional underserved needs across the women’s health category. With our life-stage-led, consumer-first approach, we are well positioned to expand into new solutions that remain clinically grounded, commercially relevant and truly aligned with what women experience in real life.